Clinical Trials Logo

Healthy Participants clinical trials

View clinical trials related to Healthy Participants.

Filter by:

NCT ID: NCT04941755 Completed - Clinical trials for Healthy Participants

A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Start date: June 25, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the effect of gastric pH changes induced by famotidine on the drug levels of BMS-986256.

NCT ID: NCT04934696 Completed - Clinical trials for Healthy Participants

A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential

Start date: August 3, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the potential for a drug-drug interaction (DDI) when BMS-986166 and hormonal oral contraceptives are co-administered.

NCT ID: NCT04926051 Completed - Clinical trials for Healthy Participants

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

Start date: June 15, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and drug levels of BMS-986172 and evaluate the effects of food on BMS-986172 absorption.

NCT ID: NCT04916769 Completed - Clinical trials for Healthy Participants

Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition

Start date: August 13, 2021
Phase: Phase 1
Study type: Interventional

This study is intended to estimate the relative bioavailability of a single 500 mg dose of bosutinib when administered as capsule contents mixed with applesauce or yogurt to intact capsules under fed condition in adult healthy participants. The comparisons will be performed using the pharmacokinetic parameters that define the rate and extent of absorption, those are Cmax and AUC. Statistical analyses will be performed comparing these parameters calculated after administration of a single 500 mg dose with the intact capsule formulation (100 mg x 5) as the Reference treatment and the capsule contents mixed with applesauce or yogurt (100 mg x 5) as the Test treatments.

NCT ID: NCT04914936 Completed - Clinical trials for Healthy Participants

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

Start date: September 21, 2014
Phase: Phase 1
Study type: Interventional

The study will evaluate one-way interaction of calcium carbonate, omeprazole, or rifampin on ACP-196.

NCT ID: NCT04901923 Completed - Clinical trials for Healthy Participants

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Start date: March 15, 2014
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety, pharmacokinetics/pharmacodynamics (PK/PD), food-effect, and drug-drug interaction study of ACP-196 in healthy participants.

NCT ID: NCT04882540 Completed - Clinical trials for Healthy Participants

A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects

Start date: May 19, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the pharmacokinetics, safety, and tolerability of brivaracetam after a single dose and multiple doses in healthy adult Chinese Study Participants.

NCT ID: NCT04882150 Completed - Clinical trials for Healthy Participants

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

Start date: May 27, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the safety, tolerability, drug levels and drug effects of BMS-986196 in healthy participants. In addition, an evaluation of food and formulation effects on BMS-986196 absorption will be performed.

NCT ID: NCT04866225 Completed - Clinical trials for Healthy Participants

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Start date: May 11, 2021
Phase: Phase 1
Study type: Interventional

This study is a Phase 1, open-label, non-randomized, 2-period, fixed-sequence, single-dose study of PF-06865571 in healthy male participants to characterize the ADME properties of [14C]PF-06865571 following oral administration; and to evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of PF-06865571 following oral administration of unlabeled PF-06865571 and IV administration of [14C]PF-06865571.

NCT ID: NCT04856293 Completed - Clinical trials for Healthy Participants

Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

Start date: April 16, 2021
Phase: Phase 1
Study type: Interventional

Bioequivalence study to evaluate the pharmacokinetics of a new crizotinib encapsulated microsphere (eMS) formulation